My oncologist has told me that we should consider immunotherapy a last resort for my metastatic lung cancer, because in early immunotherapy trials a large fraction of subjects with immune diseases had relapses (i.e., worsening of their immune disease sx). Apparently they now screen out PWMS et al. from all immunotherapy trials.
She's the lead clinician at Stanford for several cancer trials, so I'm sure she's aware of unpublished trial results, but I was wondering if this was generally known in 'the literature'.
Neither my old oncologist (who I still see) nor my Stanford MS neuro flagged immunotherapy as a potential problem.
Any thoughts?
She's the lead clinician at Stanford for several cancer trials, so I'm sure she's aware of unpublished trial results, but I was wondering if this was generally known in 'the literature'.
Neither my old oncologist (who I still see) nor my Stanford MS neuro flagged immunotherapy as a potential problem.
Any thoughts?
Comment